


NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Elafibranor for treating primary biliary cholangitis ID6331

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company	General
Ipsen Ltd (elafibranor)	All Wales Therapeutics and Toxicology
,	Centre
Patient/carer groups	Allied Health Professionals Federation
 Addenbrookes Liver Transplant 	Board of Community Health Councils in
Association	Wales
Black Health Agency	British National Formulary
British Liver Trust	Care Quality Commission
GUTS UK	Department of Health, Social Services
Liver4Life	and Public Safety for Northern Ireland
PBC Foundation	Healthcare Improvement Scotland
PSC Support	Medicines and Healthcare products
South Asian Health Foundation	Regulatory Agency
Specialised Healthcare Alliance	National Association of Primary Care
	National Pharmacy Association
Healthcare professional groups	NHS Confederation
Association of Surgeons of Great Principles of Health and He	Scottish Medicines Consortium
Britain and Ireland	Welsh Government
British Association for the Study of the Liver	Welsh Health Specialised Services
Liver	Committee
British Geriatrics SocietyBritish Liver Nurses Forum	Descible comparator companies
	Possible comparator companies
British Society of GastroenterologyRoyal College of Anaesthetists	 ADVANZ Pharma (Ursodeoxycholic acid, Obeticholic acid)
D 10 11 10 1D 131	Dr. Falk Pharma UK Ltd
 Royal College of General Practitioners Royal College of Nursing 	(Ursodeoxycholic acid)
Royal College of National Royal College of Pathologists	Galen Limited (Ursodeoxycholic acid)
 Royal College of Physicians 	Glenmark Pharmaceuticals Europe Ltd
Royal College of Surgeons	(Ursodeoxycholic acid)
 Royal College of Surgeons Royal Pharmaceutical Society 	Norgine Limited (Ursodeoxycholic acid)
Royal Society of Medicine	Strides Pharma UK Ltd
UK Clinical Pharmacy Association	(Ursodeoxycholic acid)
- On Ollilloai i Haimacy Association	Wockhardt UK Ltd (Ursodeoxycholic
Others	acid)
Department of Health and Social Care	,
NHS England	Relevant research groups
	Cochrane Hepato-Biliary Group



Consultees	Commentators (no right to submit or appeal)
	 Cochrane UK Foundation for Liver Research Genomics England MRC Clinical Trials Unit National Institute for Health Research
	 Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.